Attralus Bulletin

News, Press Releases, & Other Media
A purple and cyan fibril graphicA purple and cyan fibril graphic
In the News

Attralus Raises $25 Million to Transform Treatment for Patients with Systemic Amyloidosis

globalgenes.org
Source Author:

Rare Daily Staff

September 14, 2020
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free

Attralus has launched with $25 million in a series A financing to diagnose and potentially reverse the underlying pathology of systemic amyloid diseases.

The financing, led by VenBio Partners, will allow Attralus to further validate its pan-amyloid imaging agent, AT-01, and advance two therapeutic candidates, AT-02 and AT-03, into clinical development for ATTR (transthyretin), AL (light chain), and potentially ALECT2 systemic amyloidosis.

Attralus has launched with $25 million in a series A financing to diagnose and potentially reverse the underlying pathology of systemic amyloid diseases.

The financing, led by VenBio Partners, will allow Attralus to further validate its pan-amyloid imaging agent, AT-01, and advance two therapeutic candidates, AT-02 and AT-03, into clinical development for ATTR (transthyretin), AL (light chain), and potentially ALECT2 systemic amyloidosis.

<< Back to Bulletin

Get in Touch

Partnership, Careers, Press, OR PATIENT Inquiries

Thank you

Your message has been received!

We will reply as soon as possible.
Oops! Something went wrong while submitting the form.
A purple and cyan fibril graphic

our apologies

TABLET & MOBILE EXPERIENCES
ARE STILL UNDER CONSTRUCTION

Please view on a desktop or laptop computer.